The landscape of cancer immunotherapy was shaken as Arcus Biosciences announced the termination of a pivotal Phase 3 trial for its TIGIT-targeting drug, domvanalimab. The decision, prompted by a finding of "futility," delivers a significant setback to its partner Gilead Sciences and casts further
The translation of profound academic research into tangible technologies that address humanity's most pressing challenges stands as a hallmark of institutional excellence, a commitment exemplified by the University of California, Los Angeles. In a significant recognition of this mission, two
The home of Barbara and Dennis Meade in Ypsilanti, Michigan, is filled with the unmistakable artifacts of significant health challenges, from the walkers and wheelchairs to the oxygen tanks required for Barbara's chronic respiratory disease. Yet despite these daily realities and their shared,
A groundbreaking analysis presented at the European Association of Cardiovascular Imaging 2025 congress has shed new light on a critical and burgeoning field of medicine, revealing that treating valvular heart disease in cancer patients can dramatically improve their survival rates. As remarkable
The perplexing and often heartbreaking phenomenon of cancer recurrence following initially successful treatment has long been a central challenge in oncology, driving a significant number of cancer-related fatalities worldwide. Patients and clinicians are frequently confronted with the reality that
Today, we have the privilege of speaking with Ivan Kairatov, a biopharma expert with extensive experience in oncology research and development. We'll be dissecting the groundbreaking results from the HER2CLIMB-05 trial, a study that introduces a significant potential shift in the first-line
